Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 24.6% in March

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 4,610,000 shares, an increase of 24.6% from the February 28th total of 3,700,000 shares. Currently, 5.7% of the company’s shares are short sold. Based on an average daily trading volume, of 1,440,000 shares, the days-to-cover ratio is currently 3.2 days.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $1.90 on Tuesday. The company has a 50-day simple moving average of $2.84 and a 200-day simple moving average of $2.10. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The firm has a market capitalization of $262.74 million, a P/E ratio of -5.13 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds have recently made changes to their positions in the business. Intech Investment Management LLC bought a new stake in Compass Therapeutics in the third quarter valued at about $30,000. The Manufacturers Life Insurance Company acquired a new stake in Compass Therapeutics during the third quarter valued at approximately $79,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics in the 3rd quarter valued at approximately $37,000. Barclays PLC raised its holdings in shares of Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after buying an additional 112,614 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after buying an additional 19,095 shares during the period. Institutional investors and hedge funds own 68.43% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on CMPX shares. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target for the company. Jefferies Financial Group lifted their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Guggenheim began coverage on shares of Compass Therapeutics in a research note on Monday, February 24th. They set a “buy” rating and a $12.00 target price for the company. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.